Investigation Report on China Linezolid Market, 2010-2019
Description
Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).
Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin-resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013-2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid’s crystal form shall expire in 2021, its price stays high.
Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.
Generally speaking, linezolid enjoys a vast demand in China.
Readers can get at least the following information through this report:
Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).
Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin-resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013-2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid’s crystal form shall expire in 2021, its price stays high.
Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.
Generally speaking, linezolid enjoys a vast demand in China.
Readers can get at least the following information through this report:
- market size of linezolid in China
- major manufacturers of linezolid in the Chinese market and their market share
- retail price of linezolid in China
- market outlook of linezolid in China
- manufacturers of anti-infectious agents
- investors/ research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF LINEZOLID
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF LINEZOLID IN CHINA
2.1 Patent and Approval Status of Linezolid in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF LINEZOLID IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF LINEZOLID IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF LINEZOLID IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF LINEZOLID IN CHINESE HOSPITALS IN 2014
6.1 Fresenius Kabi
6.2 Pfizer Inc. (the US)
7 MAJOR MANUFACTURERS OF LINEZOLID IN CHINESE MARKET, 2010-2014
7.1 Pfizer Inc. (the US)
7.2 Fresenius Kabi
7.3 Pharmacia & Upjohn
8 MARKET OUTLOOK OF LINEZOLID IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF LINEZOLID IN CHINA
2.1 Patent and Approval Status of Linezolid in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF LINEZOLID IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF LINEZOLID IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF LINEZOLID IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF LINEZOLID IN CHINESE HOSPITALS IN 2014
6.1 Fresenius Kabi
6.2 Pfizer Inc. (the US)
7 MAJOR MANUFACTURERS OF LINEZOLID IN CHINESE MARKET, 2010-2014
7.1 Pfizer Inc. (the US)
7.2 Fresenius Kabi
7.3 Pharmacia & Upjohn
8 MARKET OUTLOOK OF LINEZOLID IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
SELECTED CHARTS
Chart Patent Status of Linezolid in China
Chart Approval Information of Linezolid in China
Chart Sales Status of Linezolid in Chinese Market, 2010-2014
Chart Sales Value of Linezolid in China, 2010-2014
Chart Sales Value of Linezolid in Some Regions in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Linezolid for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Made by Pfizer (the US) in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Made by Fresenius Kabi (NO) in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Injections in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Tablets in China, 2010-2014
Chart Price of Linezolid Made by Fresenius Kabi in Some Chinese Cities in 2014
Chart Price of Linezolid Made by Pfizer Inc. (the US) in Some Chinese Cities in 2014
Chart Patent Status of Linezolid in China
Chart Approval Information of Linezolid in China
Chart Sales Status of Linezolid in Chinese Market, 2010-2014
Chart Sales Value of Linezolid in China, 2010-2014
Chart Sales Value of Linezolid in Some Regions in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Linezolid for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Made by Pfizer (the US) in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Made by Fresenius Kabi (NO) in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Injections in China, 2010-2014
Chart Sales Value and Market Share of Linezolid Tablets in China, 2010-2014
Chart Price of Linezolid Made by Fresenius Kabi in Some Chinese Cities in 2014
Chart Price of Linezolid Made by Pfizer Inc. (the US) in Some Chinese Cities in 2014
